Bryn Mawr Capital Management LLC Acquires 2,672 Shares of Novo Nordisk A/S (NYSE:NVO)

Bryn Mawr Capital Management LLC raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 36.3% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,023 shares of the company’s stock after acquiring an additional 2,672 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Novo Nordisk A/S were worth $1,037,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. CNB Bank bought a new position in Novo Nordisk A/S in the 4th quarter valued at $26,000. Pacific Center for Financial Services grew its position in Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the last quarter. Valued Wealth Advisors LLC bought a new position in Novo Nordisk A/S in the 4th quarter valued at $28,000. Copeland Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock worth $26,000 after buying an additional 141 shares during the period. Finally, Bell Investment Advisors Inc lifted its holdings in shares of Novo Nordisk A/S by 79.9% in the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after buying an additional 127 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 0.9 %

Shares of NYSE NVO opened at $126.86 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The stock has a market capitalization of $569.29 billion, a P/E ratio of 46.90, a price-to-earnings-growth ratio of 2.10 and a beta of 0.41. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28. The business has a fifty day moving average price of $126.86 and a 200 day moving average price of $111.98.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. Equities research analysts expect that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were paid a $0.664 dividend. The ex-dividend date of this dividend was Friday, March 22nd. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.17%.

Wall Street Analysts Forecast Growth

NVO has been the subject of several research reports. UBS Group initiated coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. BMO Capital Markets initiated coverage on Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price for the company. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price for the company. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.